Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33 Positive Acute Myeloid Leukemia: Results from a French Retrospective Observational Study

Juliette Lambert, Emmanuel Raffoux, Delphine Lebon, Thorsten Braun, Mael Heiblig, Alberto Santagostino, Karin Gogat-Marchant, Cécile Pautas

Blood (2023) 142 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2023-179575

Published: 2023

Journal Articles

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Sylvain Garciaz, Sarah Bertoli, David A Sallman, Justine Decroocq, Pierre-Yves Dumas, Amine Belhabri, Corentin Orvain, Gaspar Aspas Requena, Celestine Simand, Kamel Laribi, Martin Carré, Alberto Santagostino, Ludovic Gabellier, Marie Anne Hospital, Ariane Mineur, Arnaud Pigneux, Norbert Vey, Christian Récher

Blood (2023) 142 (Supplement 1): 161.

https://doi.org/10.1182/blood-2023-185437

Published: 2023

Journal Articles

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Blood (2023) 142 (Supplement 1): 6741.

https://doi.org/10.1182/blood-2023-185699

Published: 2023

Journal Articles

Gilteritinib Activity in Refractory or Relapsed FLT3 -Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Blood (2022) 140 (Supplement 1): 8996–8998.

https://doi.org/10.1182/blood-2022-159125

Published: 2022

Journal Articles

Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)

Sylvain Garciaz, Justine Decroocq, Sarah Bertoli, Amine Belhabri, Pierre-Yves Dumas, Celestine Simand, Kamel Laribi, Alberto Santagostino, Martin Carre, Aline Schmidt, Gaspard Aspas Requena, Chantal Himberlin, Marie-Anne Hospital, Christian Recher, Norbert Vey

Blood (2022) 140 (Supplement 1): 6147–6148.

https://doi.org/10.1182/blood-2022-158247

Published: 2022

Journal Articles

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Blood (2022) 140 (Supplement 1): 4423–4425.

https://doi.org/10.1182/blood-2022-168742

Published: 2022

Journal Articles

Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study

Jean-Jacques Kiladjian, Françoise Boyer perrard, Kamel Laribi, Jean-Christophe Ianotto, Dana Ranta, Omar Benbrahim, Serge Bologna, Pascale Cony-Makhoul, Alberto Santagostino, Hacene Zerazhi, Abla Slimani, Olivier Fitoussi, Gabriel Etienne

Blood (2022) 140 (Supplement 1): 3968–3969.

https://doi.org/10.1182/blood-2022-156628

Published: 2022

Journal Articles

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

Blood (2022) 140 (7): 756–768.

https://doi.org/10.1182/blood.2021015328

Published: 2022

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Annalisa Arcari, MD, Annalisa Chiappella, MD, Vanessa Valenti, Luca Zanlari, MD, Monica Tani, MD, Roberto Marasca, MD, Maria Giuseppina Cabras, MD, Michele Spina, MD, Alberto Santagostino, MD, Fiorella Ilariucci, MD, Giuseppe Carli, MD, Pellegrino Musto, MD, Paolo Savini, MD, Dario Marino, MD, Francesco Ghio, MD, Massimo Gentile, MD, Maria Christina Cox, MD, Roberta Della Seta, MD, Daniele Vallisa, MD

Blood (2014) 124 (21): 3074.

https://doi.org/10.1182/blood.V124.21.3074.3074

Published: 2014

Journal Articles

Association Between Immunoparesis and a Skewed Free Light Chain (FLC) Ratio: A New Prognostic Factor Of Progression from MGUS To Multiple Myeloma?

Michele Pizzuti, Alberto Santagostino, Giuseppina Smaldore, Ida Chitarrelli, Domenico Vertone, Sara Pasquina Pascale, Angela Matturro, Immacolata Attolico, Angela Amendola, Michele Cimminiello, Nunzio Filardi, Antonella Girardi, Romina Penitente, Roberta Nuccorini, Sabrina Coluzzi, Enza Scavone

Blood (2013) 122 (21): 5314.

https://doi.org/10.1182/blood.V122.21.5314.5314

Published: 2013

Journal Articles

Evaluation Of Factor V Leiden, Prothrombin Mutations and The Homozygous mutation 677T In The MTHFR Gene In Patients With Venous Thrombosis

Michele Pizzuti, Alberto Santagostino, Maria Antonietta Rizzo, Daniela Dragonetti, Maria Grazia Pietrafesa, Immacolata Attolico, Angela Amendola, Nunzio Filardi, Michele Cimminiello, Angela Matturro, Domenico Vertone, Roberta Nuccorini, sara Pasquina Pascale, Sabrina Coluzzi

Blood (2013) 122 (21): 4798.

https://doi.org/10.1182/blood.V122.21.4798.4798

Published: 2013

Journal Articles

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

Blood (2013) 122 (16): 2799–2806.

https://doi.org/10.1182/blood-2013-03-488676

Published: 2013

Includes: Supplemental data

Journal Articles

A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide

Antonio Palumbo, MD, Alessandra Larocca, MD, Angelo Michele Carella, MD, Davide Rossi, Vittorio Montefusco, MD, Samantha Ferrari, MD, Alberto Santagostino, MD, Tommasina Guglielmelli, MD, Monica Galli, MD, Antonio Capaldi, MD, Nicola Giuliani, M.D., Ph.D., Giacinto La Verde, Paola Omedè, MD, Ileana Baldi, Mario Boccadoro, MD, Paolo Corradini, MD

Blood (2011) 118 (21): 632.

https://doi.org/10.1182/blood.V118.21.632.632

Published: 2011

Journal Articles

Treatment of Menigeal Myelomatosis with Liposomal Cytarabine (DepoCyte ® ): A Case Report

Fabio Ardizzone, Michele Sciacca, Paola Migliora, Cristina Ravanelli, Alberto Santagostino

Blood (2008) 112 (11): 5219.

https://doi.org/10.1182/blood.V112.11.5219.5219

Published: 2008

Journal Articles

5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program

Blood (2008) 112 (11): 2680.

https://doi.org/10.1182/blood.V112.11.2680.2680

Published: 2008

Journal Articles

5-Azacytidine for the Treatment of Acute Myeloid Leukemia: A Retrospective, Multicenter Study of 55 Patients.

Blood (2008) 112 (11): 1947.

https://doi.org/10.1182/blood.V112.11.1947.1947

Published: 2008

Journal Articles

Safety of Liposomal Cytarabine (DepoCyte ® ) in the Central Nervous System (CNS) Prophylaxis of Patients with Non-Hodgkin’s Lymphoma (NHL) and Acute Lymphoblastic Leukaemia: Results of a Single-Centre Experience

Fabio Ardizzone, Luciano Vitali, Michele Sciacca, Paola Migliora, Cristina Ravanelli, Alberto Santagostino

Blood (2008) 112 (11): 4961.

https://doi.org/10.1182/blood.V112.11.4961.4961

Published: 2008

Journal Articles

Bendamustine, Rituximab and Bortezomib Combined with Liposomal Ara-C (DepoCyte ® ) for CNS Prophylaxis in Relapsed/Refractory Dlbcl: A Case Report

Fabio Ardizzone, Michele Sciacca, Paola Migliora, Cristina Ravanelli, Alberto Santagostino

Blood (2008) 112 (11): 4969.

https://doi.org/10.1182/blood.V112.11.4969.4969

Published: 2008

Journal Articles

Intrathecal Therapy with Liposomal Cytarabine Plus Radiotherapy in Ph+ Acute Myeloid Leukemia Patient with Central Nervous System (CNS) Involvement.

F. Ardizzone, MD, M. Sciacca, MD, A. Zavalgia, Alberto Santagostino

Blood (2007) 110 (11): 4364.

https://doi.org/10.1182/blood.V110.11.4364.4364

Published: 2007

NARROW

Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33 Positive Acute Myeloid Leukemia: Results from a French Retrospective Observational Study

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Gilteritinib Activity in Refractory or Relapsed FLT3 -Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Association Between Immunoparesis and a Skewed Free Light Chain (FLC) Ratio: A New Prognostic Factor Of Progression from MGUS To Multiple Myeloma?

Evaluation Of Factor V Leiden, Prothrombin Mutations and The Homozygous mutation 677T In The MTHFR Gene In Patients With Venous Thrombosis

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide

Treatment of Menigeal Myelomatosis with Liposomal Cytarabine (DepoCyte ® ): A Case Report

5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program

5-Azacytidine for the Treatment of Acute Myeloid Leukemia: A Retrospective, Multicenter Study of 55 Patients.

Safety of Liposomal Cytarabine (DepoCyte ® ) in the Central Nervous System (CNS) Prophylaxis of Patients with Non-Hodgkin’s Lymphoma (NHL) and Acute Lymphoblastic Leukaemia: Results of a Single-Centre Experience

Bendamustine, Rituximab and Bortezomib Combined with Liposomal Ara-C (DepoCyte ® ) for CNS Prophylaxis in Relapsed/Refractory Dlbcl: A Case Report

Intrathecal Therapy with Liposomal Cytarabine Plus Radiotherapy in Ph+ Acute Myeloid Leukemia Patient with Central Nervous System (CNS) Involvement.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only